Maestria h2020 European research project about myopathy

Our objectives


Medical care of cardiac diseases needs to integrate more and more multiple parameters: functional and structural properties of cardiac tissues, genotype, metabolism or lifestyle. Multiple fields of expertise must be involved such as omics, biophysics of electrical signal, clinical imaging. Heterogeneous knowledge and data supporting complex and appropriate decisions to be taken by cardiologist clinicians for patient’s treatments; this new paradigm will revolutionise medical approaches and will durably impact the healthcare industry workflows starting from future emerging treatments to medical devices.

In Atrial Cardiomyopathy, characterised by a long period of clinically silent progression, and, most often, a dramatic acute clinical manifestation such as the new onset of symptomatic atrial fibrillation (AF), stroke or acute heart failure, the early detection of the disease and the recognition of precise underlying mechanisms are necessary for timely deployment of prevention strategies and personalised medical care.

The MAESTRIA project team focuses on developing novel approaches for timely detection of atrial myopathy to improve care management and identifying novel therapeutic targets for personalised medicine of AF and stroke. MAESTRIA addresses:

  • Highly personalised diagnosis by combining research results on genomic, inflammation and metabolic disorders; all involved in the progression of atrial cardiomyopathy, incorporating AF and stroke in a novel, holistic and multidisciplinary patient health pathway. MAESTRIA has the potential of preventing excess deaths, stroke, and disability in 1.5-2% of the European population, and 12-15% of Europe’s octogenarians.
  • Integration of data available from various sources by integrating mechanistic understanding of the cardiomyopathic substrate with cutting-edge imaging techniques, electrophysiological investigations and artificial intelligence approaches. Risk stratification in patients with AF will be refined, potential new therapeutic approaches to modify the natural history of AF and treatment rationalised.
  • Development and deployment of a clinically applicable digital diagnosis platform by contributing to the development of a precision medicine tool set for the contemporary management of AF and stroke across Europe and beyond. MAESTRIA will build an open-access digital platform for clinicians and patients in Europe to inform them about risk based on the outcome of our investigations.


The MAESTRIA project team aims to develop and validate the first integrative diagnostic digital platform for atrial cardiomyopathy diagnosis. This platform will be designed to provide support for improved diagnostic accuracy that increases effectiveness and efficiency of treatments, as well as prevention of the complications of atrial cardiomyopathy, such as atrial fibrillation and stroke.

#AFNET power at #DGKJahrestagung! Inspiring presentations on how to improve #afib management and therapy of cardiovascular diseases!😊#NOAHtrial @DGK_org @AGEP_DGK @danielsteven_ep

Successful Investigator and SC-Meeting for #CMRICDStudy at #DGKJahrestagung in #Mannheim! 🤩Great to discuss the positive impact our research will have on patient care! @IngoEitel @dzhk_germany #AFNET #Afib #dzhk #mrt #cardiology #NIDCM #LVEF #MRI #deathrisk #ICDtherapy

Prof. Günter Breithardt has been honoured at #DGKJahrestagung with the "AFNET Lecture on Arrhythmias Award" for his long-standing contributions to translational research into arrhythmias. 🏆Congratulations to the winner!😊 #Afib #AFNET #cardiotwitter @DGK_org @AGEP_DGK

Load More